Common stock, $0.0001 par value per share
- Symbol
- OABI
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Quarterly Report · 10-Q
OABINASDAQEQUITYCurrent
OmniAb licenses cutting-edge discovery research technology to the pharmaceutical and biotech industries and academic institutions to enable the discovery of next-generation therapeutics. The Company’s technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. This includes xPloration®, the Company's AI-powered, high-throughput single B-cell screening platform. At the heart of the OmniAb platform is something the Company calls Biological Intelligence™, which powers the immune systems of its proprietary, transgenic animals to create optimized candidates for human therapeutics. The Company primarily derives revenue from license fees for technology access, milestones from partnered programs and service revenue from research programs as well as revenue associated with the xPloration platform.
OMNIAB, INC. · 10-Q · Filed 2026-08-06